NCT03197805 - Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

May 28, 2019

Study Completion Date

May 28, 2019

Conditions

Breast Cancer

Interventions

DIAGNOSTIC_TEST

PAM 50 test

Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.

Trial Locations (16)

13009

Institut Paoli Calmettes, Marseille

14000

Centre François Baclesse, Caen

21079

Centre Georges François Leclerc, Dijon

25030

CHRU Jean Minoz, Besançon

31059

Institut Claudius Regaud, Toulouse

33076

Institut Bergonie, Bordeaux

34298

Institut de Cancérologie de Montpellier, Montpellier

38043

CHU Albert Michalon, Grenoble

44805

Institut de Cancérologie de l'Ouest, Saint-Herblain

51056

Institut Jean Godinot, Reims

51100

Institut du Cancer COURLANCY, Reims

54519

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

63000

Centre Jean Perrin, Clermont-Ferrand

67065

Centre Paul Strauss, Strasbourg

69373

Centre Léon Bérard, Lyon

87042

Hopital DUPUYTREN, Limoges